Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bausch & Lomb Corp (BLCO)

Bausch & Lomb Corp (BLCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,457,595
  • Shares Outstanding, K 355,081
  • Annual Sales, $ 5,101 M
  • Annual Income, $ -360,000 K
  • EBIT $ 371 M
  • EBITDA $ 810 M
  • 60-Month Beta 0.58
  • Price/Sales 1.11
  • Price/Cash Flow 9.52
  • Price/Book 0.86
  • Price/Earnings ttm 31.78
  • Earnings Per Share ttm 0.50
  • Most Recent Earnings $0.32 on 02/18/26
  • Next Earnings Date 04/29/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    SIC-3851 Ophthalmic Goods

    Medical Services

Options Overview Details

View History
  • Implied Volatility 70.87% (+17.55%)
  • Historical Volatility 33.63%
  • IV Percentile 65%
  • IV Rank 23.61%
  • IV High 187.31% on 11/19/25
  • IV Low 34.89% on 12/23/25
  • Expected Move (DTE 18) 0.99 (6.46%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 321
  • Volume Avg (30-Day) 273
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 3,900
  • Open Int (30-Day) 3,602
  • Expected Range 14.27 to 16.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.06
  • Number of Estimates 5
  • High Estimate 0.14
  • Low Estimate 0.02
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +185.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.14 +0.79%
on 03/30/26
18.42 -17.16%
on 03/02/26
-3.04 (-16.61%)
since 02/27/26
3-Month
15.14 +0.79%
on 03/30/26
18.92 -19.32%
on 02/25/26
-1.92 (-11.18%)
since 12/26/25
52-Week
10.45 +46.03%
on 04/30/25
18.92 -19.32%
on 02/25/26
+1.13 (+8.00%)
since 03/28/25

Most Recent Stories

More News
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April...

BLCO.TO : 21.28 (-0.14%)
BLCO : 15.26 (-0.72%)
3 Reasons BLCO is Risky and 1 Stock to Buy Instead

3 Reasons BLCO is Risky and 1 Stock to Buy Instead

BLCO : 15.26 (-0.72%)
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Both primary effectiveness endpoints were met, demonstrating statistically significant and clinically meaningful intraocular pressure reduction. ELIOS is an implant-free procedure that...

BLCO.TO : 21.28 (-0.14%)
BLCO : 15.26 (-0.72%)
Bausch + Lomb Launches R&D “Teach-in” Webinar Series

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series...

BLCO.TO : 21.28 (-0.14%)
BLCO : 15.26 (-0.72%)
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know

Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know

UHS : 182.10 (-1.05%)
IART : 9.12 (-0.87%)
GEHC : 68.77 (-0.66%)
BLCO : 15.26 (-0.72%)
ICUI : 125.38 (+0.96%)
2 Profitable Stocks Worth Investigating and 1 We Ignore

2 Profitable Stocks Worth Investigating and 1 We Ignore

FRSH : 8.04 (+2.16%)
AZZ : 121.09 (-1.33%)
BLCO : 15.26 (-0.72%)
5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call

5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call

BLCO : 15.26 (-0.72%)
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Global review highlights increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies and environmental exposures LUMIFY redness reliever...

BLCO.TO : 21.28 (-0.14%)
BLCO : 15.26 (-0.72%)
3 Small-Cap Stocks We Steer Clear Of

3 Small-Cap Stocks We Steer Clear Of

BLCO : 15.26 (-0.72%)
NVAX : 8.09 (-4.26%)
VNT : 34.21 (-2.56%)
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus

BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus

BLCO : 15.26 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R)....

See More

Key Turning Points

3rd Resistance Point 15.84
2nd Resistance Point 15.67
1st Resistance Point 15.47
Last Price 15.26
1st Support Level 15.10
2nd Support Level 14.93
3rd Support Level 14.73

See More

52-Week High 18.92
Fibonacci 61.8% 15.68
Last Price 15.26
Fibonacci 50% 14.68
Fibonacci 38.2% 13.68
52-Week Low 10.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.